Samodzielny Publiczny Szpital Kliniczny Im.Andrzeja Mieleckiego SUM W Katowicach
- Address
- Ul. Francuska 20/24, 40-027 Katowice, Poland
Hemic and Lymphatic Diseases
At Samodzielny Publiczny Szpital Kliniczny Im.Andrzeja Mieleckiego SUM W Katowicach, research in Hemic and Lymphatic Diseases focuses on serious blood cancers and related conditions, including acute myeloid leukemia, multiple myeloma, and advanced classical Hodgkin lymphoma. The trials are designed to assess new treatment approaches and improve outcomes for patients with difficult-to-treat disease.
- Evaluating new therapies for acute myeloid leukemia and other aggressive blood cancers
- Studying treatment effectiveness in multiple myeloma with relapse or minimal residual disease
- Comparing frontline options for advanced classical Hodgkin lymphoma
This area reflects a strong clinical interest in improving survival and disease control through better cancer treatment strategies.
Immune System Diseases
Clinical research in Immune System Diseases at this site includes work on chronic graft versus host disease, a complex immune-related complication that can follow transplant care. The studies aim to test whether newer treatments can better manage symptoms and improve long-term patient outcomes.
- Testing a new therapy for chronic graft versus host disease
- Comparing active treatment with placebo-based supportive care
- Seeking better control of immune complications after transplant
This research supports more effective management of post-transplant immune disorders in a specialized hematology setting.
Neoplasms
The site also conducts studies in Neoplasms, with a particular emphasis on hematologic cancers such as acute leukemia, multiple myeloma, and Hodgkin lymphoma. These trials are intended to improve treatment effectiveness, delay disease progression, and explore whether adding new medicines to standard care can offer better results.
- Assessing new combinations for acute myeloid leukemia
- Investigating preventive treatment strategies in multiple myeloma
- Comparing standard therapy with newer options in Hodgkin lymphoma
Overall, the oncology research portfolio is centered on finding more effective ways to treat cancers with limited existing options.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 therapeutic areas and 15 of 62 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 49 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 14 by active trials.
- 1Polish Myeloma Consortium2active
lock +13 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Polish Myeloma Consortium3trials
lock +4 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Samodzielny Publiczny Szpital Kliniczny Im.Andrzeja Mieleckiego SUM W Katowicach
lock Showing 1 of 24 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects with End Stage Kidney Disease Undergoing Dialysis | CSL Behring LLC | Phase IV | Recruiting | Jul 2023 | — |
IMP list
lock Showing 1 of 62 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cytarabine | 3 | Unknown | 2024-10-23 | 2025-12-19 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.